Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
Clinical studies (e.g. Vermeulen & Comhaire, 1978) show tamoxifen substantially raises LH, FSH and testosterone in men over courses of 10 days to 6 weeks, all through natural pathway stimulation, not exogenous hormone administration. FDA-approved for breast cancer with extensive safety data since the 1970s. Used for PCT and gynecomastia (~70% response rate in the cited crossover trial). Rated 2 as a supportive compound that restores natural hormone production rather than enhancing beyond natural.
Overview
A first-generation non-steroidal Selective Estrogen Receptor Modulator (SERM) that has been the gold standard for PCT since the 1970s. Acts as an estrogen antagonist in breast tissue and the hypothalamus/pituitary (stimulating LH/FSH release) while acting as an agonist in bone (protective) and liver. The cornerstone of most PCT protocols.
Important Warnings
- •MUST AVOID CYP2D6 inhibitors - they block conversion to active endoxifen, making tamoxifen ineffective
- •Avoid: Fluoxetine (Prozac), Paroxetine (Paxil), Bupropion (Wellbutrin), Duloxetine (Cymbalta)
- •Safe alternatives if antidepressant needed: Citalopram, Escitalopram, Sertraline, Venlafaxine
- •Contraindicated with warfarin/blood thinners - significantly increases bleeding risk
- •Elevated blood clot risk in men - monitor for DVT/PE symptoms
- •May upregulate progestin receptors - use caution with 19-nor steroids
- •Levels persist for 6+ weeks after discontinuation due to long half-life
Purpose & Use Cases
Post Cycle Therapy (PCT)
Stimulates natural testosterone production by blocking estrogen negative feedback at the hypothalamus, increasing GnRH pulsatility and subsequent LH/FSH release.
Gynecomastia Prevention
Blocks estrogen at breast tissue receptors, preventing and potentially reversing gynecomastia. ~70% response rate in the cited double-blind crossover trial (Parker 1986).
On-Cycle Gyno Protection
Can be used during cycle at lower doses (10-20mg/day) specifically to prevent gynecomastia without affecting systemic estrogen levels.
Testosterone Restoration
A classic study (Vermeulen & Comhaire, 1978) found 20mg/day for 10 days produced a moderate rise in LH, FSH, testosterone and estradiol in normal men; longer ~6-week courses have also been shown to significantly raise LH/FSH/testosterone via the same negative-feedback-blocking mechanism, though exact percentage increases vary between studies.
Benefits
- Proven PCT efficacy with decades of use
- Specifically targets breast tissue - effective gyno prevention
- Does not lower systemic estrogen (preserves estrogen benefits)
- Bone-protective estrogenic effects
- Long half-life allows for flexible dosing
- Generally well-tolerated compared to Clomid
- Fewer vision and mood side effects than Clomid
Good to Know
Why a SERM is "selective" - and why that matters
Tamoxifen does not lower estrogen; it blocks or activates the estrogen receptor depending on the tissue. It is an antagonist in breast tissue (blocking gyno) and at the hypothalamus (removing negative feedback to raise LH/FSH and restart testosterone), but an agonist in bone (protective) and liver. That tissue selectivity is exactly why it treats gyno and restarts the axis while preserving estrogen's benefits elsewhere - something an aromatase inhibitor cannot do.
SERM vs AI for gyno - block the receptor, do not crash estrogen
For gynecomastia, tamoxifen blocks estrogen at the breast receptor directly, so you fix the problem without dropping systemic estrogen. An AI instead lowers estrogen body-wide, which risks joint pain, low libido and mood/lipid problems from crashed estrogen. This is why the standard advice is to keep Nolvadex on hand for gyno symptoms rather than reaching for more AI.
It is a prodrug - CYP2D6 activates it (do not block that enzyme)
Tamoxifen itself is relatively weak; the liver enzyme CYP2D6 converts it into endoxifen, which is 30-100x more potent at the receptor. Drugs that inhibit CYP2D6 - notably the antidepressants fluoxetine (Prozac), paroxetine (Paxil) and bupropion (Wellbutrin) - can therefore make tamoxifen far less effective by starving it of its active metabolite. If an antidepressant is needed, sertraline, citalopram, escitalopram or venlafaxine are safer choices.
The gold-standard PCT - and timing by ester
The classic protocol is 40/40/20/20 (mg/day across four weeks). Start timing depends on the last compound: roughly 2-3 weeks after a long-ester injectable, or 3-5 days after an oral/short-ester, so that suppressive drug levels have fallen before you try to restart the axis. HCG beforehand and/or Clomid alongside can speed recovery.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 10 – 20 mg/day |
| Intermediate | 20 – 40 mg/day |
| Advanced | 20 – 40 mg/day |
Standard PCT: 40mg/day weeks 1-2, 20mg/day weeks 3-4. For on-cycle gyno prevention: 10-20mg/day. For treating active gyno: 20mg/day for 6-12 weeks. Can be combined with Clomid for enhanced PCT (~30% faster testosterone recovery).
Side Effects
Hot Flashes
very commonMost common side effect, affecting ~64% of users in clinical studies.
Usually tolerable and transient.
Blood Clot Risk (DVT/PE)
rareMen on tamoxifen have >2x higher risk of blood clots. Risk highest in first 18 months (81% of clots occurred in this window in one study). Men over 71 at highest risk.
Avoid if history of blood clots. Watch for warning signs: leg swelling/pain (DVT), chest pain/shortness of breath (PE). Seek emergency care if suspected.
Mood Changes
uncommonDepression and mood swings reported in some users, though less common than with Clomid.
Usually transient. Lower dose if problematic.
Nausea
commonAffects approximately 26% of users.
Take with food.
Decreased Libido/ED
uncommonReported in some men, typically recovers after stopping.
Usually resolves after PCT completion.
Hair Thinning
uncommonReported in approximately 5% of users.
Typically reverses after discontinuation.
General Mitigation Strategies
Generally well-tolerated at PCT doses. Watch for signs of blood clots - this is the most serious risk. Do not use if you have a history of DVT/PE or are on anticoagulants. The long half-life means side effects may persist for weeks after stopping.
Post Cycle Therapy (PCT)
Tamoxifen IS a PCT drug. Standard protocol: 40/40/20/20 (mg/day for 4 weeks). Start 2-3 weeks after last long-ester injection, or 3-5 days after last oral/short-ester dose. Can be combined with Clomid and/or preceded by HCG for enhanced recovery.
How It Works
Tamoxifen is a prodrug metabolized by CYP2D6 to its primary active metabolite endoxifen, which has 100-fold greater affinity for estrogen receptors and 30-100x greater potency than the parent drug. It competitively binds to estrogen receptors with tissue-selective effects: antagonist in breast tissue (blocking gyno), antagonist in hypothalamus (removing negative feedback, increasing GnRH, LH, FSH), and agonist in bone (preventing bone loss).
Fundamentals
Reference on the practices relevant to Tamoxifen: how they are done and where they go wrong. Not a recommendation to use it.
Common Stacks
- Tamoxifen + Clomid - Combined PCT for faster recovery (~30% improvement)
- HCG (2 weeks) followed by Tamoxifen (4 weeks) - Standard PCT sequence
- Low-dose Tamoxifen (10-20mg) during cycle for gyno prevention
Legal Status
FDA-approved prescription medication for breast cancer treatment and prevention.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
Tamoxifen is explicitly prohibited as an anti-estrogenic substance / SERM under S4.2.